Matthew Taylor
Stock Analyst at Jefferies
(2.72)
# 2,071
Out of 4,966 analysts
176
Total ratings
62.04%
Success rate
11.47%
Average return
Main Sectors:
Stocks Rated by Matthew Taylor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SI Shoulder Innovations | Initiates: Buy | $19 | $14.82 | +28.21% | 1 | Aug 25, 2025 | |
| ABT Abbott Laboratories | Upgrades: Buy | $143 → $145 | $132.66 | +9.30% | 14 | Jul 18, 2025 | |
| INMD InMode | Maintains: Hold | $16 → $15 | $14.94 | +0.40% | 7 | Apr 14, 2025 | |
| GEHC GE HealthCare Technologies | Upgrades: Buy | $95 → $103 | $73.73 | +39.70% | 2 | Jan 8, 2025 | |
| EW Edwards Lifesciences | Downgrades: Hold | $85 → $70 | $81.34 | -13.94% | 19 | Sep 18, 2024 | |
| PODD Insulet | Maintains: Neutral | $211 → $223 | $339.88 | -34.39% | 14 | Aug 9, 2024 | |
| MDT Medtronic | Maintains: Sell | $75 → $76 | $92.81 | -18.11% | 17 | May 24, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $125 | $2.17 | +5,660.37% | 1 | Feb 9, 2024 | |
| MASI Masimo | Downgrades: Hold | $107 → $121 | $139.71 | -13.39% | 9 | Jan 30, 2024 | |
| OBIO Orchestra BioMed Holdings | Initiates: Buy | $14 | $2.73 | +412.82% | 1 | Jan 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $45 | $12.51 | +259.71% | 2 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $0.5 | $0.46 | +8.81% | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $58 → $53 | $15.13 | +250.30% | 2 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $22 → $24 | $11.55 | +107.79% | 2 | May 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $320 → $345 | $391.41 | -11.86% | 14 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Hold | $115 → $130 | $106.10 | +22.53% | 8 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $272.64 | -15.64% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $16.67 | +19.98% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $85 | $54.36 | +56.36% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $75 | $61.27 | +22.41% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $245 | $274.51 | -10.75% | 7 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $62 | $24.69 | +151.11% | 8 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $126.41 | +66.13% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $15.90 | -24.53% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $125 | $75.34 | +65.91% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $105.50 | -52.61% | 1 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $210 | $473.30 | -55.63% | 12 | Oct 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $96 | $56.37 | +70.30% | 3 | Feb 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $7 | $1.61 | +334.78% | 1 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $266 | $192.98 | +37.84% | 4 | May 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $17 → $16 | $10.26 | +55.95% | 2 | Jul 19, 2017 |
Shoulder Innovations
Aug 25, 2025
Initiates: Buy
Price Target: $19
Current: $14.82
Upside: +28.21%
Abbott Laboratories
Jul 18, 2025
Upgrades: Buy
Price Target: $143 → $145
Current: $132.66
Upside: +9.30%
InMode
Apr 14, 2025
Maintains: Hold
Price Target: $16 → $15
Current: $14.94
Upside: +0.40%
GE HealthCare Technologies
Jan 8, 2025
Upgrades: Buy
Price Target: $95 → $103
Current: $73.73
Upside: +39.70%
Edwards Lifesciences
Sep 18, 2024
Downgrades: Hold
Price Target: $85 → $70
Current: $81.34
Upside: -13.94%
Insulet
Aug 9, 2024
Maintains: Neutral
Price Target: $211 → $223
Current: $339.88
Upside: -34.39%
Medtronic
May 24, 2024
Maintains: Sell
Price Target: $75 → $76
Current: $92.81
Upside: -18.11%
Allurion Technologies
Feb 9, 2024
Initiates: Buy
Price Target: $125
Current: $2.17
Upside: +5,660.37%
Masimo
Jan 30, 2024
Downgrades: Hold
Price Target: $107 → $121
Current: $139.71
Upside: -13.39%
Orchestra BioMed Holdings
Jan 19, 2024
Initiates: Buy
Price Target: $14
Current: $2.73
Upside: +412.82%
Oct 2, 2023
Maintains: Buy
Price Target: $47 → $45
Current: $12.51
Upside: +259.71%
Jul 19, 2023
Initiates: Underperform
Price Target: $0.5
Current: $0.46
Upside: +8.81%
Jul 12, 2023
Upgrades: Buy
Price Target: $58 → $53
Current: $15.13
Upside: +250.30%
May 24, 2023
Maintains: Hold
Price Target: $22 → $24
Current: $11.55
Upside: +107.79%
May 2, 2023
Maintains: Buy
Price Target: $320 → $345
Current: $391.41
Upside: -11.86%
Mar 31, 2023
Upgrades: Hold
Price Target: $115 → $130
Current: $106.10
Upside: +22.53%
Oct 12, 2022
Initiates: Buy
Price Target: $230
Current: $272.64
Upside: -15.64%
Oct 12, 2022
Initiates: Buy
Price Target: $20
Current: $16.67
Upside: +19.98%
Oct 12, 2022
Initiates: Hold
Price Target: $85
Current: $54.36
Upside: +56.36%
Oct 12, 2022
Initiates: Buy
Price Target: $75
Current: $61.27
Upside: +22.41%
Oct 12, 2022
Initiates: Hold
Price Target: $245
Current: $274.51
Upside: -10.75%
Oct 12, 2022
Initiates: Hold
Price Target: $62
Current: $24.69
Upside: +151.11%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $126.41
Upside: +66.13%
Oct 12, 2022
Initiates: Buy
Price Target: $12
Current: $15.90
Upside: -24.53%
Oct 12, 2022
Initiates: Buy
Price Target: $125
Current: $75.34
Upside: +65.91%
Oct 12, 2022
Initiates: Buy
Price Target: $50
Current: $105.50
Upside: -52.61%
Oct 12, 2022
Initiates: Hold
Price Target: $210
Current: $473.30
Upside: -55.63%
Feb 24, 2022
Upgrades: Buy
Price Target: $96
Current: $56.37
Upside: +70.30%
Dec 17, 2021
Initiates: Neutral
Price Target: $7
Current: $1.61
Upside: +334.78%
May 13, 2019
Upgrades: Overweight
Price Target: $266
Current: $192.98
Upside: +37.84%
Jul 19, 2017
Maintains: Equal-Weight
Price Target: $17 → $16
Current: $10.26
Upside: +55.95%